Breaking News
April 22, 2019 - The U.S government may account for up to $37.8 billion due to opioid epidemic
April 22, 2019 - Improving ACA’s Insurance Coverage Provisions will lead to better care for patients
April 22, 2019 - Study identifies possible therapeutic effects of curcumin on stomach cancer
April 22, 2019 - Hyaline fibromatosis syndrome – Genetics Home Reference
April 22, 2019 - Scientists use CRISPR for possible ‘bubble boy’ therapy
April 22, 2019 - Hematologist (and a mom, singer, actress and much more) stands up for diversity
April 22, 2019 - Novel AI voice tool can help diagnose PTSD
April 22, 2019 - Overlooked part of cell’s internal machinery may hold key to treating acute myeloid leukemia
April 22, 2019 - MIT scientists reverse some behavioral symptoms of rare neurodevelopmental disorder
April 22, 2019 - Scientists find new therapy target for drug-induced liver failure
April 22, 2019 - Opioid dose variability could lead to increased risk of overdose, study suggests
April 22, 2019 - Newly developed model predicts salmonella outbreaks several months in advance
April 22, 2019 - Deep-learning model better predicts survival outcomes for lung cancer
April 22, 2019 - One in Three U.S. Adults Aged 35 to 44 May Have Drinking Problem
April 22, 2019 - Why the measles virus is so contagious
April 22, 2019 - Magnet ‘Zap’ to the Brain Might Jumpstart Aging Memory
April 22, 2019 - Immune response to gut microbes may be early indicator of type 1 diabetes
April 22, 2019 - Destination Limbo: Health Suffers Among Asylum Seekers In Crowded Border Shelter
April 22, 2019 - Research shows how dopamine contributes to sex differences in worms
April 22, 2019 - Marijuana users weigh less compared to non-users
April 22, 2019 - Research uncovers critical RNA processing aberrations in ALS and FTD
April 22, 2019 - Many cancer patients use marijuana and prescription opioids, study reveals
April 22, 2019 - Frailty may up fracture risk in patients with type 2 diabetes
April 22, 2019 - Study provides new insight into how obesity, insulin resistance can affect cognition
April 22, 2019 - Study seeks to better understand the genetic causes for hypospadias
April 22, 2019 - FDA grants approval of first generic naloxone nasal spray to treat opioid overdose
April 22, 2019 - FDA authorizes marketing of first medical device to treat ADHD
April 22, 2019 - Vanderbilt researchers to develop and test ‘safe harbor’ standards of care
April 22, 2019 - You’re probably brushing your teeth wrong – here are four tips for better dental health
April 22, 2019 - Pharmacy closures contribute to medication non-adherence among heart patients
April 22, 2019 - Using Edge AI technology to observe behavior of cattle
April 22, 2019 - Bacteria play a role in the development of stomach ulcers in pigs
April 22, 2019 - Hand Hygiene Compliance Poor in Task Transitions
April 22, 2019 - smoking could harm your baby
April 22, 2019 - Scientists identify rare, paradoxical response to antiretroviral therapy
April 21, 2019 - More TV, Tablets, More Attention Issues at Age 5
April 21, 2019 - Drug reduces risk of kidney failure in people with diabetes, study finds
April 21, 2019 - New research identifies novel link between antibiotic resistance and climate change
April 21, 2019 - Simple intervention can provide lasting protection for teens against junk food marketing
April 21, 2019 - The protein p38-gamma identified as a new therapeutic target in liver cancer
April 21, 2019 - Novel system enables researchers to study bacteria within mini-tissues in a dish
April 21, 2019 - Discovery of oral cancer biomarkers could save thousands of lives
April 21, 2019 - Geneva Exhibition committee gives gold medals to two medications developed by Kazan
April 21, 2019 - Scientists aim to minimize or eliminate hair loss during cancer treatment
April 21, 2019 - WiFi interacts with signaling pathways in the human brain
April 21, 2019 - Stroke Hospitalizations Down in Black, White Medicare Enrollees
April 21, 2019 - First common risk genes discovered for autism
April 21, 2019 - Researchers map auditory sensory system of the mouse brain
April 21, 2019 - Scientists Bring Pig’s Brain, Dead 4 Hours, Back to ‘Cellular Activity’
April 21, 2019 - Virtual reality a promising tool for reducing fears and phobia in autism
April 21, 2019 - New analysis lists out opportunities for U.S. medical schools to advance population health
April 21, 2019 - More sleep may help teens with ADHD focus and organize
April 21, 2019 - Breakthrough antibody treatment suppresses HIV without antivirals
April 21, 2019 - AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1
April 21, 2019 - Is your hand pain arthritis, carpal tunnel or something else?
April 21, 2019 - Measles outbreaks may become more frequent if vaccination rates continue to decline
April 21, 2019 - Researchers succeed in accelerating process of creating 3D images
April 21, 2019 - Tiny worm mimics key genetic risk for Alzheimer’s
April 21, 2019 - Angry dreams explained by brain waves
April 20, 2019 - Parenteral Antimicrobial Tx at Home Burdens Children’s Caregivers
April 20, 2019 - Diabetes treatment may keep dementia, Alzheimer’s at bay
April 20, 2019 - New bandage-like biosensor collects and analyzes sweat
April 20, 2019 - A comprehensive, centralized database of bovine milk compounds
April 20, 2019 - Two new epigenetic regulators maintain self-renewal of embryonic stem cells
April 20, 2019 - New Evidence That Veggies Beat Steak for Heart Health
April 20, 2019 - Study reveals genes associated with heavy drinking and alcoholism
April 20, 2019 - Texas A&M AgriLife becomes the newest member of NutriRECS international consortium
April 20, 2019 - In most states, insurance won’t cover addiction treatments
April 20, 2019 - Computer-based memory games may be beneficial for individuals with fragile X syndrome
April 20, 2019 - Timing of food intake influences molecular clock in the liver of mice
April 20, 2019 - Precise decoding of breast cancer cells paves way for new treatment option
April 20, 2019 - Scientists use 3D imaging to help model complex processes performed by placenta
April 20, 2019 - MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
April 20, 2019 - Genetic variants that protect against obesity could aid new weight loss medicines
April 20, 2019 - New technology developed for microscopic imaging in living organisms
April 20, 2019 - when quitting cigarettes, consider using more nicotine, not less
April 20, 2019 - Key proteins can block Listeria without triggering the death of host cells
April 20, 2019 - Researchers create a working model of cerebral tract to study brain function
April 20, 2019 - New study shows that microbes can help break toxic chemical in dust
April 20, 2019 - Scientists use NIR light and injected DNA nanodevice to guide stem cells to injury
FDA Approves First Drug for Postpartum Depression, Zulresso (brexanolone)

FDA Approves First Drug for Postpartum Depression, Zulresso (brexanolone)

image_pdfDownload PDFimage_print

WEDNESDAY, March 20, 2019 — Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it.

The drug, Zulresso (brexanolone), is delivered via intravenous infusion.

“Postpartum depression is a serious condition that, when severe, can be life-threatening,” noted the FDA’s Dr. Tiffany Farchione. “Women may experience thoughts about harming themselves or harming their child.”

The condition “can also interfere with the maternal-infant bond,” added Farchione, who is acting director of the Division of Psychiatry Products in the agency’s Center for Drug Evaluation and Research.

The FDA decision “marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option,” she said in an agency statement.

Psychiatrist Dr. Martha Wald agreed that women battling postpartum depression have long needed new options.

“There is tremendous stigma around postpartum depression for women,” said Wald, a psychiatrist and psychoanalyst at Duke University, in Winston-Salem, N.C. “Many women experience great shame and feel inadequate as mothers if they struggle with depression at a time that is supposed to be joyous.”

“Because of this stigma, many women choose to not seek help and endure great suffering in silence,” she said. “Postpartum depression affects 15 to 20 percent of the general population, and at least half of this group goes untreated. As more targeted treatments like this become available, more mothers are likely to seek and benefit from treatment.”

Works in a new way

Dr. Kristina Deligiannidis was the lead investigator on the clinical trials that led to Zulresso’s approval. She said the drug acts in a way that’s different from other antidepressants.

Zulresso “acts on the main inhibitory neurotransmitter system in the brain, the GABA system,” explained Deligiannidis, who helps direct women’s behavioral health at Zucker Hillside Hospital, in Glen Oaks, N.Y.

The drug’s active ingredient is synthetic allopregnanolone, a steroid that the body also makes naturally.

“Allopregnanolone is known to modulate the stress response system in humans, which has been shown to be abnormally functioning in women with postpartum depression,” Deligiannidis explained.

And unlike typical antidepressants, which take four to six weeks to show an effect, Zulresso “works fast — in 60 hours patients had reduced depression severity,” she added.

According to the FDA, the results of two clinical trials led to Zulresso’s approval — one involved women with moderate postpartum depression, while the other involved women with a more severe form of the illness.

In both trials, women received intravenous infusions of either the drug or a placebo, and their depression symptoms were then tracked for a month.

In both cases, Zulresso outperformed the “dummy” placebo infusion.

Safety concerns

Deligiannidis said the drug was largely safe, with headache (about 16 percent of patients), dizziness (about 14 percent) and sleepiness (nearly 11 percent) being the most common side effects.

In rare cases, however, sedation was so profound that a loss of consciousness occurred, Deligiannidis said.

“In those patients that experienced loss of consciousness, this resolved within 15 minutes, and all excessive sedation events were completely resolved within 90 minutes,” she said. “In three cases, the infusion was restarted and concluded without recurrence of events.”

However, because of this rare side effect, the FDA has mandated that a boxed warning accompany the drug. Patients who take Zulresso will need to be counseled on the risks of treatment, and the 60-hour (2.5 days) infusion must be done at a health care facility where the patient can be monitored. Until any sedating effect wears off, people who take Zulresso should not drive or operate machinery, the agency said.

Dr. Jennifer Wu is an obstetrician/gynecologist at Lenox Hill Hospital, in New York City. She wasn’t involved in the development of the drug, but called it a “welcome option” for women.

Still, the fact that it needs to be administered in a specialized facility, and not at home, is a drawback, she said.

“Due to possibly needing to separate the mother and child, this would likely not be a first-line drug for postpartum depression,” Wu said.

More information

There’s more on postpartum depression at the American College of Obstetricians and Gynecologists.

© 2019 HealthDay. All rights reserved.

Posted: March 2019

Tagged with:

About author

Related Articles